X0306 4 2021-10-04 0 0001816736 Gemini Therapeutics, Inc. /DE GMTX 0001581754 Tananbaum James B. C/O GEMINI THERAPEUTICS, INC. 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 1 0 1 0 Common Stock 1500000 I See footnote Common Stock 2928750 I See footnote Common Stock 411500 I See footnote Stock Option (Right to Buy) 3.80 2021-10-04 4 A 0 17245 0.00 A 2021-10-03 Common Stock 17245 17245 D This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCM V LLC") and Foresite Capital Opportunity Management V, LLC ("FCOM V LLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMV LLC, FCOMV LLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V of FCOM V and may be deemed to have sole voting and dispositive power over these shares. (continued from footnote 2) Each Reporting Person disclaims the existence of a "group." Each of FCM V, FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. /s/ Jason Meyenburg, attorney-in-fact 2021-10-06